Prospective, single-center, double blind, double dummy, randomized trial. Platelet function tests and adenosine levels were assessed at baseline and 15 days after taking Ticagrelor with Prasugrel placebo or Prasugrel with Ticagrelor placebo in stable patients with coronary artery disease
This was a prospective, double blinded, randomized trial that compared platelet inhibition and adenosine levels with ticagrelor (180mg loading dose, followed by 90 mg BID) versus prasugrel (60mg loading dose, followed by 10 mg QD) . Patients were eligible if they were between 18 and 75 years old, were on aspirin without P2Y12 inhibitor at baseline and \> 1 year after documented ACS. Platelet aggregation was compared with the Multiplate ADP® assay, performed at baseline and after 15 days on study medication. Adenosine plasma levels were measured with high performance liquid chromatography at the same time points
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
87
Compared platelet inhibition and adenosine levels at baseline and after 15 days
Compared platelet inhibition and adenosine levels at baseline and after 15 days
Heart Institute (InCor) / University of São Paulo
São Paulo, São Paulo, Brazil
To compare platelet inhibition between the two groups (ticagrelor and prasugrel)
Platelet aggregation was compared with the Multiplate ADP® assay at baseline and after 15 days on study medication
Time frame: 15 days
To compare adenosine levels between the two groups (ticagrelor and prasugrel)
Adenosine plasma levels were measured at baseline and after 15 days with high performance liquid chromatography at the same time points
Time frame: 15 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.